This study investigates the efficacy and safety of lisaftoclax, a novel BCL-2 inhibitor, in combination with pomalidomide and dexamethasone (Pd) or daratumumab, lenalidomide, and dexamethasone (DRd) in patients with relapsed/refractory multiple myeloma (R/R MM) and lisaftoclax with Pd in R/R AL amyloidosis. Lisaftoclax has shown promising antitumor activity in hematologic malignancies, prompting its evaluation in these settings.

Key Points:

• Lisaftoclax, a BCL-2 inhibitor, combined with Pd or DRd, demonstrated clinical benefit in R/R MM and R/R AL amyloidosis.
• Patients treated with lisaftoclax combinations achieved significant response rates, including complete and partial responses.
• Safety analysis indicated manageable adverse events, predominantly hematologic, with no significant drug-drug interactions observed.
• This study supports further investigation of lisaftoclax-based regimens in these challenging hematologic malignancies.

Authors:
Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Jack Khouri, MD, Costas K. Yannakou, MBBS, PhD, Zi Chen, MD, PhD, Yanyan Wang, MD, Huanshan Guo, MD, Hengbang Wang, PhD, Mingyu Li, PhD, Mohammad Ahmad, MD, Dajun Yang, MD, PhD, Yifan Zhai, MD, PhD